Suven Life Sciences Limited


2014| 2013| 2012| 2011| 2010| 2009 |2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001


July 11, 2014
-Suven to Present at Alzheimer's Association International Conference (AAIC)

June 04, 2014
-Suven Life secures One (1) Product Patent in USA

May 26, 2014
-Suven Investor/Analyst Conference Call Transcript

May 22, 2014
-Suven’s PAT up by 367% for the year ended March 2014 & proposed regular and one time special silver jubilee year dividend aggregating to 250%

May 19, 2014
-Suven Life secures (3) Product Patents in Australia, South Korea and China

April 10, 2014
-Suven Life secures (2) Product Patents for their NCEs in Canada and Hong Kong

Mar 26, 2014
-Suven Life secures (2) Product Patents for their NCEs in USA

Mar 04, 2014
-Suven grants an exclusive license & right to distribute its Malathion Lotion in USA, CANADA and MEXICO to Taro Pharmaceuticals

Feb 06, 2014
-Suven Investor/Analyst Conference Call Transcript

Feb 14, 2014
-Suven Life secures (2) Product Patents for their NCEs in New Zealand

Feb 04, 2014
-Suven Q3 PAT up by 370% to Rs.36.43 Cr

Jan 31, 2014
-Suven Life secures (3) Product Patents for their NCEs in Canada, China and India

Jan 22, 2014
-SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCE

Jan 09, 2014
-Suven Life secures three (3) Product Patents for their NCEs in Australia, Sri Lanka and South Korea

2013 Top

 Nov 13, 2013
-Suven Investor/Analyst Conference Call Transcript

Nov 11, 2013
-Suven Q2 PAT up by 602% to Rs.45.55 Cr

Nov 08, 2013
-Suven Life Sciences presenting the positive pharmacology data of 4 NCEs at Society for Neuroscience (SFN-2013) Annual Meeting at San Diego, USA

Nov 05, 2013
-Suven Life secures two (2) Product Patents for their NCEs in USA and Japan

Sept 25, 2013
-Suven Life secures three (3) Product Patents for their NCEs in New Zealand, Singapore and South Korea

Aug 13,2013
-Suven Q1 PAT up by 274% to Rs.29.77 Cr

Aug 08,2013
-Suven Life secures two (2) Product Patents for their NCEs in Europe

July 12,2013
-Suven to Present at Alzheimer's Association International Conference (AAIC)

June 28,2013
-Suven Life Sciences secures two (2) Product Patents for their NCEs in Japan and USA

May 14, 2013
-Suven‘s PAT up by 115% for the year ended Mar 2013

May 10, 2013
-Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia.

April 17, 2013
-Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New Zealand

Feb 12, 2013
-Suven‘s PAT up by 500 % for the quater ended Dec 2012

2012 Top

Dec 31, 2012
-Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada.

Dec 13, 2012
-Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea

Nov 15, 2012
-Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012

Oct 04, 2012
-Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”

Aug 14, 2012
-Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012

Aug 09, 2012
-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New Zealand.

July 13, 2012
-Suven to Present at Alzheimer's Association International Conference (AAIC)

May 22, 2012
-Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and Eurasia

May 04, 2012
-Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012

April 03, 2012
-Suven Life Sciences secures 4 Product Patents for their NCEs in China and Korea

February 07, 2012
-Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA

January 31, 2012
-Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011

2011 Top

December 08, 2011
-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and Canada

November 14, 2011
-Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-2011) Annual Meeting at Washington DC, USA

November 1, 2011
-Suven‘s revenue up by 31% and spends 18% of revenue on R&D;

October4, 2011
-Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”

September 22, 2011
-Suven Participating at 4th CNS Partnering & Deal Making Conference in USA

September 5, 2011
-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New Zealand

August 18, 2011
-Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the world

August 13, 2011
-Suven‘s revenue up by 24% and spends 17% of revenue on R&D

July 18, 2011
-Suven presenting at International Conference on Alzheimer’s disease (ICAD)

June 20, 2011
-Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world

May 30, 2011
-Suven Spends 20.5% of Revenue on R&D
  PAT up by 48.55% for the year ending March 2011

May 26, 2011
-Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the world

May 18, 2011
-Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS)

May 09, 2011
-Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”

April 26, 2011
-Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world

April 5, 2011
-SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCE

Jan 31, 2011
-Suven spends 24% of revenue on R&D
  PAT up by 55% for for the 3rd quarter ending Dec 2010

Jan 11, 2011
-Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011

2010 Top

Dec 30, 2010
-Suven Life Sciences secures 2 Product Patents For Their NCEs

Dec 23, 2010
-Suven Life Sciences secures 4 Product Patents For Their NCEs

Nov 12, 2010
-Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting (SFN-2010) at San Diego, USA

Oct 27 2010
-Suven spends 21% of revenue on R&D
 PAT up by 23% for the half year

Sep 27 2010
-Suven Life Sciences bags Pharmexcil's Gold “Patent Award”

Sep 21 2010
-Suven Life Sciences secures Two US Patents on NCEs

Sep 8 2010
-Suven Secures 8th product patent Both in Australia and Mexico

July 27 2010
-Suven spends 22% of revenue on R&D
 PAT up by 58% for the 1st Quarter

July 12 2010
-Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)

June 16 2010
-Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE’s to treat Central Nervous System (CNS) disorders

May 25 2010
-Suven’s partnering and fundraising activity at C21 BioVentures™

May 12 2010
-Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCE

May 3 2010
-Prof. Syed Hasnain joins Suven as Additional Director

Apr 30 2010
-Suven spends 26% of Revenue on R&D for the year ended March 2010

Apr 28 2010
-Suven Life Sciences secures Product Patents from India and New Zealand

Apr 22 2010
-Suven Life Sciences secures Three Australian Patents on NCEs

Apr 12 2010
-Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE to treat Central Nervous System (CNS) disorders

Mar 29 2010
-Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders

Mar 22 2010
-Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System (CNS) disorders

Jan 27 2010
-Suven spends 34% of Revenue on R&D for the 3rd quarter ending Dec’ 09

Jan 12 2010
-Suven Secures Two product patents in China and Russia

2009 Top

Dec 14 2009
-Suven Secures two Product patents from Canadian Intellectual Property Office

Nov 30 2009
-Suven Life Sciences secures Three European Patents on NCEs

Oct 31 2009
-Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09

Oct 20 2009
-Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2009 at Chicago, USA

Oct 14 2009
-Suven’s Clinical Candidate SUVN-502 For Alzheimer’s disease Secures product patents in several Key markets in the world

Sep 14 2009
-Suven Life Sciences secures Two US Patents on NCEs

Sep 07 2009
-Suven achieves 1st Milestone payment in Drug Discovery collaboration

July 28 2009
-Suven’s profit up by 37%, Spends 22% of Revenue on R&D .

July 27 2009
-Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer’s disease at ICAD 2009, Vienna, Austria.

May 6 2009
-SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.

Apr 29 2009
-Suven’s revenue up by 19%, Spends 22% of Revenue on R&D.

Apr 9 2009
-Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland.

Jan 19 2009
-Suven’s revenue up by 21%, Spends 24% of Revenue on R&D.

Jan 13 2009
-Suven participation at Biotech Showcase 2009.

2008 Top

Nov 18 2008
-Suven participation at Bio-Europe 2008.

Nov 11 2008
-Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held from 10-12 November 2008

Oct 31 2008
Suven's net up by 50%, Spends 17% of Revenue on R&D

Oct 13 2008
-SUVN-502 data being presented at 16th BioPartnering in London

Sep 29 2008
-Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in Switzerland

Sep 25 2008
-DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer’s disease

Aug 18 2008
-Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride

Aug 4 2008
-Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer’s conference, Chicago and Drug Discovery conference, Boston

Jul  25 2008
-Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland for Alzheimer’s Disease

Jul  7 2008
-Suven Life Sciences Clinical candidate SUVN-502 being presented at International Conference on Alzheimer’s Disease, ICAD-2008 at Chicago, USA

Jun 18 2008
-Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s disease

May 27 2008
-Suven Life Sciences gets Two product patents for NCEs in Russia and Australia

May 20 2008
-Suven Life Sciences gets Two product patents for NCEs in South Africa and China

May 5 2008
-Suven's Clinical Candidate SUVN-502 Secures European Product Patent

Apr 26 2008
-Revenue growth at 7.44%, R&D spent at 24.53% of Revenue
-17 Product Patents obtained during the qtr globally
-Establishes Second CNS Drug Discovery Collaboration with Lilly

Mar 31 2008
-Suven Life Sciences gets Two Product patents in Korea and Mexico

Mar 24 2008
-Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region)

Mar 12 20088
-Suven Establishes second CNS Drug Discovery Collaboration with Lilly

Jan 28 2008
-Suven Revenue stands flat, R&D spent at 25% of Revenue
obtains 2 US, 3 European and 4 Indian Product Patents during the  qtr

Jan 23 2008
-Suven obtains  2nd Product Patent from US Patent office

2007 Top

Dec 27 2007
-Suven obtains  1st Product Patent from US Patent office

Dec 11 2007
-Suven presenting at Windhover's Bio/Pharma Partnerships conference in San Francisco

Nov  27 2007
-Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases.

 Nov 05 2007
-Suven Life Sciences presenting Pre-clinical data of their NCE's at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA

Oct  31 2007
-Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs)

Oct  30 2007
-Suven's half yearly revenues increase by 10%, R&D spent at 26% of Revenue

Oct 25 20077
-Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection

Oct 23 2007
-Suven Life Sciences Secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs)

Jul 31 2007
-Suven PAT up by 51%;R&D spend at 33% of Revenue

Jul 12 2007
-Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 in India to conduct Phase 1 clinical trials

Jul 5 2007
-Suven Life Sciences presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia

Jun 11 2007
-Suven's unit III receives US FDA acceptance

Apr 26 2007
-Suven yearly revenues increase by 38%, PAT up by 33% ; R&D spend at 24% of Revenue

Jan 29 2007
-Suven Income up by 35%, Spends 17% on R&D
-Suven shares split from Rs 2 per share to Re. 1 per share and issues bonus shares in the ratio of 1:1

Jan 1 2007

-Suven renewed ISO 14001 certification

-Suven renewed ISO 9001 certification

-Suven received OHSAS 18001 certification

 

2006 Top


Sep 20 2006

Suven receives NABL certification

Aug 29 2006

Suven and Lilly Establish Drug Discovery Collaboration

Aug 16 2006

Preclinical Data on Suven’s 5-HT6 antagonists for CNS diseases to be presented at Neuroscience 2006

Jul 31 2006
SUVEN’s quarterly revenues increase by 60%, PAT up by 51%; R&D spend at 16% of Revenue

2005 Top


Nov 21 2005
Suven Life Sciences presented Pre-clinical data of their NCEs at Society for Neuroscience (SFN) Annual Meeting, Washington DC, USA

Oct 11 2005
Suven Awarded Phase III Clinical study for Chronic Low Back pain.

Oct 03 2005
-Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan


2004 Top


Dec 2004

-Suven Life Sciences ropes in global contract research industry veteran

Oct 2004
-Suven pharma promoter invests $1-m in CRO, data development


Apr 2004
-Suven Life Sciences net Income up by 27.76%


Apr 27, 2004
-Suven Life income up 10 p.c.

Mar 23, 2004
-Suven to set up Rs 100 cr unit in Vizag

Feb 5, 2004
-Suven Life Sciences net up 57 percent

Feb 1, 2004
-Suven profit up 5% to Rs. 1.91 cr in Q3

Jan 1, 2004
-Suven gets ISO 14001 certification

2003 Top

Dec 18, 2003
-Suven Life to raise Rs 27.4 cr through preferential issue
-Borregaard exits Suven Life Sciences

Dec 5, 2003
-Suven board okays merger of subsidiary
-Suven Life board decides to split shares

Nov 28, 2003
-Suven board to consider merger of subsidiary
-Suven Life Sciences may merge arm with self
-Suven plans pref issue, share split, merger of arm

Nov 24, 2003
-Suven graduating itself to life sciences player

Oct 23, 2003
-The $15 billion bulk drug opportunity
-CPhI: Downpour of deals

Sep 29, 2003
-Venkat Jasti re-elected president of BDMA

Sep 6, 2003
-Spurious drugs eating into AP’s export share

Aug 07, 2003
-Suven Pharma rechristened Suven Life

Aug 02, 2003
-Suven Pharma is Suven Life now

August 01, 2003
-Suven Q1 net up 63% at Rs 2.3 cr

Jul 7, 2003
-PA fellowship Award

Jun12, 2003
-Venkat Jasti asks Govt. & Industry to play pro-active role to tap the potential post-2005

Jun 2, 2003
-Venkat Jasti joins Pharmabiz advisory board

May 20, 2003
-SUVEN Pharma acquires assets of New Jersey (USA) based SYNTHON CHIRAGENICS

Apr 26, 2003
-SUVEN spent 21 % of its revenue in R & D

Apr 21, 2003
-SUVEN eyes discovery research

Mar 25, 2003
-Drug discovery boutique set up
-3 Indian Pharma form alliance
-Desi Pharma trio ally for new patent regime
-Life sciences alliance formed — 3 pharma cos tie up with US firm
-3 cos. forge alliance with U.S. firm
-3 drug firms join hands

 

2002 Top

Dec 24, 2002
-SUVEN Pharma sees revenue jump after April 2004

Oct 18, 2002
-SUVEN starts research academy
-SUVEN Pharma to collaborate in promoting the Centre of Excellence in clinical research

Aug 07 , 2002
-SUVEN sets the stage for Contract Research in India

Jun 03 , 2002
-Speeding up drug discovery

 

2001 Top

Dec 25, 2001
-Pharma sector hopes to have Export Promotion Council soon
-Andhra Pradesh to set up Pharma City

Dec 24, 2001
-After IT and BT, Pharma catches Chandrababu Naidu's eye
-Forget IT, Pharma is the new mantra
-Pharmaexcil
-Seperate Export Promotion Council for pharma sector on anvil
-Pharmaexcil likely to be operational 

Dec 23, 2001
-Pharma City in Vizag

Dec 21, 2001
-Vizag's Pharma City to get a booster dose
-Vizag Pharma City Phase-I to be operational by 2003

Nov 23, 2001
-A.P. to attract global majors as healthcare capital

Nov 1, 2001
-SUVEN Pharma

  Top